Equities research analysts forecast that Novavax, Inc. (NASDAQ:NVAX) will report $547.57 million in sales for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for Novavax’s earnings. The highest sales estimate is $1.19 billion and the lowest is $78.57 million. Novavax posted sales of $279.66 million during the same quarter last year, which suggests a positive year-over-year growth rate of 95.8%. The firm is scheduled to announce its next earnings report on Monday, March 7th.
On average, analysts expect that Novavax will report full year sales of $1.53 billion for the current fiscal year, with estimates ranging from $1.00 billion to $2.12 billion. For the next financial year, analysts forecast that the company will report sales of $5.19 billion, with estimates ranging from $3.05 billion to $7.95 billion. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that follow Novavax.
Novavax (NASDAQ:NVAX) last released its earnings results on Thursday, November 4th. The biopharmaceutical company reported ($4.31) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($4.04) by ($0.27). Novavax had a negative return on equity of 149.66% and a negative net margin of 89.31%. The business had revenue of $178.80 million during the quarter, compared to analysts’ expectations of $347.34 million. During the same period in the prior year, the company earned ($3.21) earnings per share. The firm’s quarterly revenue was up 13.9% compared to the same quarter last year.
NVAX stock traded down $0.64 during trading on Thursday, hitting $200.07. 2,916,347 shares of the stock traded hands, compared to its average volume of 4,601,239. Novavax has a 1 year low of $94.67 and a 1 year high of $331.68. The firm’s 50 day moving average is $181.58 and its two-hundred day moving average is $193.04. The stock has a market cap of $15.13 billion, a price-to-earnings ratio of -13.51 and a beta of 1.28. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.24 and a quick ratio of 1.43.
In other news, insider Gregory M. Glenn sold 1,386 shares of the stock in a transaction that occurred on Tuesday, August 31st. The shares were sold at an average price of $239.87, for a total value of $332,459.82. Following the transaction, the insider now owns 5,394 shares in the company, valued at approximately $1,293,858.78. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director David M. Mott sold 24,961 shares of the stock in a transaction that occurred on Thursday, September 23rd. The stock was sold at an average price of $252.90, for a total transaction of $6,312,636.90. The disclosure for this sale can be found here. Insiders have sold a total of 226,332 shares of company stock worth $43,023,648 in the last 90 days. Company insiders own 2.10% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the stock. Annapolis Financial Services LLC purchased a new stake in Novavax in the 2nd quarter worth approximately $32,000. Firestone Capital Management increased its holdings in Novavax by 200.0% in the 2nd quarter. Firestone Capital Management now owns 150 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 100 shares in the last quarter. Quadrant Capital Group LLC increased its holdings in Novavax by 58.1% in the 2nd quarter. Quadrant Capital Group LLC now owns 166 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 61 shares in the last quarter. Itau Unibanco Holding S.A. purchased a new stake in Novavax in the 2nd quarter worth approximately $37,000. Finally, Knuff & Co LLC purchased a new stake in Novavax in the 2nd quarter worth approximately $42,000. 52.77% of the stock is owned by institutional investors.
Novavax, Inc focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.